MedPath

贵州阜康仁制药有限公司

Ownership
-
Established
2016-08-02
Employees
-
Market Cap
-
Website
http://www.gzlkzb.com

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

11

NMPA:11

Drug Approvals

Entecavir oral solution

Product Name
恩替卡韦口服溶液
Approval Number
国药准字H20253587
Approval Date
Mar 11, 2025
NMPA

Levetiracetam in sodium chloride injection

Product Name
左乙拉西坦氯化钠注射液
Approval Number
国药准字H20253254
Approval Date
Jan 24, 2025
NMPA

Oxaliplatin Injection

Product Name
奥沙利铂注射液
Approval Number
国药准字H20249605
Approval Date
Dec 1, 2024
NMPA

Desloratadine oral solution

Product Name
地氯雷他定口服溶液
Approval Number
国药准字H20233919
Approval Date
Oct 15, 2024
NMPA

Levetiracetam Oral Solution

Product Name
左乙拉西坦口服溶液
Approval Number
国药准字H20244954
Approval Date
Sep 19, 2024
NMPA

Gemcitabine Hydrochloride for Injection

Product Name
注射用盐酸吉西他滨
Approval Number
国药准字H20244270
Approval Date
Jun 28, 2024
NMPA

Gemcitabine Hydrochloride for Injection

Product Name
注射用盐酸吉西他滨
Approval Number
国药准字H20244269
Approval Date
Jun 28, 2024
NMPA

Palonosetron Hydrochloride Injection

Product Name
盐酸帕洛诺司琼注射液
Approval Number
国药准字H20244107
Approval Date
Jun 25, 2024
NMPA

Palonosetron Hydrochloride Injection

Product Name
盐酸帕洛诺司琼注射液
Approval Number
国药准字H20244106
Approval Date
Jun 25, 2024
NMPA

Moxifloxacin Hydrochloride and Sodium Chloride Injection

Product Name
盐酸莫西沙星氯化钠注射液
Approval Number
国药准字H20243201
Approval Date
Feb 23, 2024
NMPA
  • Prev
  • 1
  • 2
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.